INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors

被引：1
|
作者：
Farren, Matthew R.
Roman, Valerie
Gallion, Alexandra
Allali-Hassani, Abdellah
Sokolsky, Alexander
Kong, Weixi
Smith, Amanda
Wang, Hui
Correa, Gina
Deller, Marc
Epling, Leslie B.
Procak, Jessica
Zhang, Guofeng
Pecko, Katherine
Kennedy, Keith
Boer, Jason
Kurzeja-Lipinski, Kerri
Covington, Maryanne
Chen, Kwang-Jong
Wallower, Renee
Rocha, Jennifer
Pan, Rina
Perry, Anthony
Yuska, Brad
Wang, Xiaozhao
Macarron, Ricardo
Kim, Sunkyu
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5900
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5900
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
    Ye, Qinda
    Shvartsbart, Artem
    Li, Zhenwu
    Gan, Pei
    Policarpo, Rocco L.
    Qi, Chao
    Roach, Jeremy J.
    Zhu, Wenyu
    Mccammant, Matthew S.
    Hu, Bin
    Li, Gencheng
    Yin, Haolin
    Carlsen, Peter
    Hoang, Gia
    Zhao, Le
    Susick, Robert
    Zhang, Fenglei
    Lai, Cheng-Tsung
    Hassani, Abdellah Allali
    Epling, Leslie B.
    Gallion, Alexandra
    Kurzeja-Lipinski, Kerri
    Gallagher, Karen
    Roman, Valerie
    Farren, Matthew R.
    Kong, Weixi
    Deller, Marc C.
    Zhang, Guofeng
    Covington, Maryanne
    Diamond, Sharon
    Kim, Sunkyu
    Yao, Wenqing
    Sokolsky, Alexander
    Wang, Xiaozhao
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (02) : 1924 - 1939
  • [2] Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor
    Li, Xin
    Shen, Feng
    Zhang, Limin
    Wang, Wei
    Kong, Luyao
    Bao, Yong
    Mao, Yuchang
    Wang, Zaiyong
    Lin, Sophie
    Zhang, Zhe
    Feng, Jun
    Hu, Min
    He, Feng
    CANCER RESEARCH, 2024, 84 (06)
  • [3] MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors
    Lakhani, Nehal J.
    Melisi, Davide
    Subbiah, Vivek
    Ammakkanavar, Natraj Reddy
    O'Reilly, Eileen M.
    Cassier, Philippe Alexandre
    Wainberg, Zev A.
    Duffy, Austin G.
    Patnaik, Amita
    Fujiwara, Yutaka
    Oberstein, Paul Eliezer
    Garcia-Carbonero, Rocio
    Wright, Jennifer
    Lin, Aimee K.
    Li, Jian
    Axelson, Michael D.
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS845 - TPS845
  • [4] Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor
    Iyer, Chandrasekar
    Li, Binghui
    Stewart, Trent R.
    Wang, Tao
    Capen, Andrew
    Cavitt, Rachel
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Zhao, Gaiying
    Rodriguez, Michael J.
    Carballares, Santiago
    Cooke, Andrew
    Bondi, Robert
    Burns, Lee
    Kelamangalath, Lakshmi
    Wallace, Ross
    Kolakowski, Gabrielle
    Henry, James R.
    Si, Chong
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [5] LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
    Gong, Xueqian
    Gao, Hong
    Bender, Mark H.
    Ming, Wenyu
    Zhang, Youyan
    Stewart, Trent R.
    Yu, Chun Ping
    Xu, Wei Guo
    You, Aurthur Xintian
    Bian, Wen Ting
    Li, Binghui
    Wang, Tao
    Bian, Huimin
    Tandon, Manuj
    Capen, Andrew
    Cavitt, Rachel N.
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Klippel, Anke
    Iyer, Chandrasekar
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Inhibition of KRAS G12D mutant with small molecules
    Lee, Dae-Hee
    Lee, Ji Yoon
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Site-specific mutagenesis screening in KRAS G12D mutant library to uncover resistance mechanisms to KRAS G12D inhibitors
    Choi, Jeesoo
    Shin, Ju-young
    Kim, Taeyul K.
    Kim, Kiwook
    Kim, Jiyun
    Jeon, Eunhye
    Park, Juyeong
    Han, Yoon Dae
    Kim, Kyung-A
    Sim, Taebo
    Kim, Hui Kwon
    Kim, Han Sang
    CANCER LETTERS, 2024, 591
  • [8] A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
    Zhou, C.
    Li, W.
    Song, Z.
    Zhang, Y.
    Zhang, Y.
    Huang, D.
    Yang, Z.
    Zhou, M.
    Mao, R.
    Huang, C.
    Li, X.
    Wang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1273
  • [9] Targeting KRAS G12D mutant tumors with the PROTAC degrader RP03707
    Ji, Xiang
    Li, Huanping
    Wu, Gang
    Zhang, Qiguo
    He, Xiaolin
    Wu, Yanpeng
    Zong, Bing
    Xu, Xiaojin
    Liang, Chao
    Wang, Beibei
    Zhang, Yuwei
    Hu, Qingyao
    Zhou, Jiaxin
    Guo, Weihui
    Bai, Bing
    Wang, Lin
    Ai, Jinchao
    Zhang, Leduo
    Zhou, Honggui
    Sun, Shihao
    Wang, Yijie
    Wang, Youhong
    Fan, Qiming
    Chen, Dawei
    Zhou, Tianlun
    Lu, Jiasheng
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors
    Cheng, Hengmiao
    Li, Puhui
    Chen, Ping
    Irimia, Adriana
    Bae, Jae Hyun
    Brooun, Alexei
    Fagan, Patrick
    Lam, Richard
    Lin, Bingzhen
    Zhang, Jingchuan
    Zhan, Xuejun
    Wu, Xu
    Xie, Nan
    Chiang, Gary
    Shoemaker, Robert
    Vernier, Jean-Michel
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (10): : 1351 - 1357
12345